Personalis (NASDAQ:PSNL) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Personalis (NASDAQ:PSNL) issued its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06), FiscalAI reports. The firm had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.49 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%.

Here are the key takeaways from Personalis’ conference call:

• Personalis reported strong clinical volume momentum with 7,800 NeXT Personal tests in Q1 (26% sequential, 258% YoY), surpassed >1,000 ordering physicians in the quarter, and reconfirmed a 2026 clinical volume target of 43,000–45,000 tests.
• Q1 revenue was $15.5M (down ~25% YoY) and gross margin compressed to 1.8% due to unreimbursed scaling; net loss widened to $30M and full-year net loss is guided to about $105M with ~$100M expected cash usage despite a $233M cash balance.
• Reimbursement and clinical evidence progress: Medicare coverage for breast and lung surveillance is live, MolDX submissions are pending for neoadjuvant breast and pan‑cancer IO, and presented data (NEOPRISM‑CRC, DARWIN‑2, 10k real‑world cohort) highlighted high negative predictive value and the value of ultrasensitivity.
• Biopharma MRD momentum and backlog are growing: Q1 biopharma MRD revenue was $3.1M with management targeting $20M–$21M for the full year, expecting most MRD revenue to ramp in H2 as several large trials commence.

Personalis Stock Down 0.2%

NASDAQ PSNL traded down $0.01 during trading hours on Friday, hitting $5.98. The company had a trading volume of 2,726,536 shares, compared to its average volume of 1,603,522. The firm has a market cap of $625.97 million, a P/E ratio of -6.57 and a beta of 1.96. Personalis has a fifty-two week low of $3.84 and a fifty-two week high of $11.50. The business has a fifty day simple moving average of $6.93 and a 200-day simple moving average of $8.23.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PSNL. Legal & General Group Plc bought a new stake in shares of Personalis during the 2nd quarter worth about $30,000. BNP Paribas Financial Markets boosted its holdings in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Personalis by 184.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock valued at $44,000 after acquiring an additional 3,592 shares during the period. Focus Partners Wealth acquired a new position in shares of Personalis during the first quarter valued at approximately $47,000. Finally, AQR Capital Management LLC bought a new stake in Personalis during the fourth quarter worth approximately $82,000. Institutional investors own 61.91% of the company’s stock.

Analysts Set New Price Targets

PSNL has been the subject of a number of research reports. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Morgan Stanley decreased their price target on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Guggenheim boosted their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Needham & Company LLC raised their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.50.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.